Carcinoma, Renal Cell Clinical Trial
Official title:
Preoperative Imaging Diagnostic Evaluation Model Based on Evidence-based Pathological Diagnose Criteria for Renal Cell Carcinoma Tumor Thrombus With Inferior Vena Cava Wall Invasion
NCT number | NCT05589207 |
Other study ID # | M2022597 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | January 1, 2023 |
Est. completion date | January 1, 2027 |
The goal of this observational study is to establish a preoperative imaging diagnostic model which highly consistent with the histopathological examinations, as well as a accurate and systematic pathological grading standard of inferior vena cava (IVC) vascular wall invasion in renal cell carcinoma (RCC) with tumor thrombus invading vascular wall.The main questions it aims to answer are: - To establish a preoperative imaging diagnostic model which highly consistent with the histopathological examinations. - To determine what impact does different vascular wall layer invasion make on the long-term prognosis in RCC with IVC tumor thrombus; - To determine which layer invasion according to pathological examination make sense to clinical treatment (can significantly affect prognosis); Participants with IVC vascular wall invasion/ non-invasion are divided into experimental group (invaded group) or control group (non-invaded group) respectively according to pathological examinations, in order to establish a prospective cohort with three-year follow-up. The pathological characteristics of local recurrence and poor prognosis are summarized, and postoperative pathological diagnostic criteria of IVC vascular wall invasion and established. The local recurrence and distant recurrence outcomes are compared between experiment group and control group, in order to analyze the long-term influence of vascular wall invasion. Then the preoperative imaging diagnostic evaluation model will be established.
Status | Recruiting |
Enrollment | 232 |
Est. completion date | January 1, 2027 |
Est. primary completion date | January 1, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Adults =18 years of age; - Accepted abdominal ultrasonography, contrast-induced ultrasonography, enhanced CT and MRI before the surgery; - Diagnosis of primary renal cell carcinoma with tumor thrombus before and during the surgery; - Received radical nephrectomy and at least one kind of thrombectomy (including IVC incision only, IVC partial resection, IVC diagonal resection, and IVC segmental resection) - Can tolerate the surgery; - Eastern Cooperative Oncology Group Performance Status Scale (ECOG-PS) 0~2; - No previous history of malignant tumor; - Willing to return for required follow-up visits Exclusion Criteria: - Failed to receive standard nephrectomy for any reason; - Attached other addition operations in the surgery; - Received neoadjuvant treatment before the surgery; - Experience any other conditions that may affect the curative effect (e.g. active tuberculosis, autoimmune disease, or oral glucocorticoids treatment); - Experience serious consequences or death due to anesthesia accident during operation; |
Country | Name | City | State |
---|---|---|---|
China | Peking University Third Hospital | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Peking University Third Hospital |
China,
Abaza R. Initial series of robotic radical nephrectomy with vena caval tumor thrombectomy. Eur Urol. 2011 Apr;59(4):652-6. doi: 10.1016/j.eururo.2010.08.038. Epub 2010 Sep 16. — View Citation
Adams LC, Ralla B, Bender YY, Bressem K, Hamm B, Busch J, Fuller F, Makowski MR. Renal cell carcinoma with venous extension: prediction of inferior vena cava wall invasion by MRI. Cancer Imaging. 2018 May 3;18(1):17. doi: 10.1186/s40644-018-0150-z. — View Citation
Bocardo Fajardo G, Arellano Ganan R, Gonzalez Lopez L, Fernandez Gonzalez I, Blanco Gonzalez J, Garrido Abad P, Coloma del Peso A, Pereira Sanz I. [Prognostic significance of the microscopic invasion of the renal vein wall in renal cell cancer]. Arch Esp Urol. 2009 Oct;62(8):630-8. doi: 10.4321/s0004-06142009000800004. Spanish. — View Citation
Hirono M, Kobayashi M, Tsushima T, Obara W, Shinohara N, Ito K, Eto M, Takayama T, Fujii Y, Nishikido M, Kimura G, Kishida T, Takahashi M, Miyao N, Naya Y, Abe T, Fujioka T, Ito K, Naito S; Members of the Japanese Society of Renal Cancer. Impacts of clinicopathologic and operative factors on short-term and long-term survival in renal cell carcinoma with venous tumor thrombus extension: a multi-institutional retrospective study in Japan. BMC Cancer. 2013 Oct 2;13:447. doi: 10.1186/1471-2407-13-447. — View Citation
Ingels A, Campi R, Capitanio U, Amparore D, Bertolo R, Carbonara U, Erdem S, Kara O, Klatte T, Kriegmair MC, Marchioni M, Mir MC, Ouzaid I, Pavan N, Pecoraro A, Roussel E, de la Taille A. Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma. Nat Rev Urol. 2022 Jul;19(7):391-418. doi: 10.1038/s41585-022-00592-3. Epub 2022 May 11. — View Citation
Labbate C, Hatogai K, Werntz R, Stadler WM, Steinberg GD, Eggener S, Sweis RF. Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy. J Immunother Cancer. 2019 Mar 11;7(1):66. doi: 10.1186/s40425-019-0546-8. — View Citation
Lakatos E. Designing complex group sequential survival trials. Stat Med. 2002 Jul 30;21(14):1969-89. doi: 10.1002/sim.1193. — View Citation
Lakatos E. Sample sizes based on the log-rank statistic in complex clinical trials. Biometrics. 1988 Mar;44(1):229-41. Erratum In: Biometrics 1988 Sep;44(3):923. — View Citation
Lang H, Lindner V, Saussine C, Havel D, Faure F, Jacqmin D. Microscopic venous invasion: a prognostic factor in renal cell carcinoma. Eur Urol. 2000 Nov;38(5):600-5. doi: 10.1159/000020338. — View Citation
Lardas M, Stewart F, Scrimgeour D, Hofmann F, Marconi L, Dabestani S, Bex A, Volpe A, Canfield SE, Staehler M, Hora M, Powles T, Merseburger AS, Kuczyk MA, Bensalah K, Mulders PF, Ljungberg B, Lam TB. Systematic Review of Surgical Management of Nonmetastatic Renal Cell Carcinoma with Vena Caval Thrombus. Eur Urol. 2016 Aug;70(2):265-80. doi: 10.1016/j.eururo.2015.11.034. Epub 2015 Dec 23. — View Citation
Li QY, Li N, Huang QB, Luo YK, Wang BJ, Guo AT, Ma X, Zhang X, Tang J. Contrast-enhanced ultrasound in detecting wall invasion and differentiating bland from tumor thrombus during robot-assisted inferior vena cava thrombectomy for renal cell carcinoma. Cancer Imaging. 2019 Dec 2;19(1):79. doi: 10.1186/s40644-019-0265-x. — View Citation
Liu Z, Li L, Hong P, Zhu G, Tang S, Zhao X, Zhang Q, Wang G, He W, Zhang H, Xue H, Cui L, Ge H, Jiang J, Zhang S, Cao F, Yan J, Ma F, Liu C, Ma L, Wang S. A Predictive Model for Tumor Invasion of the Inferior Vena Cava Wall Using Multimodal Imaging in Patients with Renal Cell Carcinoma and Inferior Vena Cava Tumor Thrombus. Biomed Res Int. 2020 Oct 6;2020:9530618. doi: 10.1155/2020/9530618. eCollection 2020. — View Citation
Liu Z, Li Y, Zhao X, Ge L, Zhu G, Hong P, Tang S, Zhang S, Tian X, Wang S, Liu C, Zhang H, Ma L. Renal cell carcinoma with tumor thrombus growing against the direction of venous return: an indicator of complicated surgery and poor prognosis. BMC Surg. 2021 Dec 28;21(1):443. doi: 10.1186/s12893-021-01448-0. — View Citation
Liu Z, Zhang Q, Zhao X, Zhu G, Tang S, Hong P, Ge L, Zhang S, Wang G, Tian X, Zhang H, Liu C, Ma L. Inferior vena cava interruption in renal cell carcinoma with tumor thrombus: surgical strategy and perioperative results. BMC Surg. 2021 Nov 21;21(1):402. doi: 10.1186/s12893-021-01400-2. — View Citation
Liu Z, Zhao X, Zhang HX, Li LW, Tang SY, Wang GL, Zhang SD, Wang SM, Ma LL, Tian XJ. Surgical complexity and prognostic outcome of small volume renal cell carcinoma with high-level venous tumor thrombus and large volume renal cell carcinoma with low-level thrombus. Chin Med J (Engl). 2019 Aug 5;132(15):1780-1787. doi: 10.1097/CM9.0000000000000352. — View Citation
Rodriguez Faba O, Linares E, Tilki D, Capitanio U, Evans CP, Montorsi F, Martinez-Salamanca JI, Libertino J, Gontero P, Palou J. Impact of Microscopic Wall Invasion of the Renal Vein or Inferior Vena Cava on Cancer-specific Survival in Patients with Renal Cell Carcinoma and Tumor Thrombus: A Multi-institutional Analysis from the International Renal Cell Carcinoma-Venous Thrombus Consortium. Eur Urol Focus. 2018 Apr;4(3):435-441. doi: 10.1016/j.euf.2017.01.009. Epub 2017 Feb 9. — View Citation
Shi T, Huang Q, Liu K, Du S, Fan Y, Yang L, Peng C, Shen D, Wang Z, Gao Y, Gu L, Niu S, Ai Q, Li H, Liu F, Li Q, Wang H, Guo A, Fu B, Yang X, Zhang X, Wang D, Wang D, Guo H, Li H, Olivero A, Fam XI, Ma X, Wang B, Zhang X. Robot-assisted Cavectomy Versus Thrombectomy for Level II Inferior Vena Cava Thrombus: Decision-making Scheme and Multi-institutional Analysis. Eur Urol. 2020 Oct;78(4):592-602. doi: 10.1016/j.eururo.2020.03.020. Epub 2020 Apr 15. — View Citation
Sun Z, Cui Y, Xu C, Yu Y, Han C, Liu X, Lin Z, Wang X, Li C, Zhang X, Wang X. Preoperative Prediction of Inferior Vena Cava Wall Invasion of Tumor Thrombus in Renal Cell Carcinoma: Radiomics Models Based on Magnetic Resonance Imaging. Front Oncol. 2022 Jun 6;12:863534. doi: 10.3389/fonc.2022.863534. eCollection 2022. — View Citation
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. — View Citation
Ueki H, Terakawa T, Ueno Y, Sofue K, Horii S, Okamura Y, Bando Y, Hara T, Furukawa J, Harada K, Hinata N, Nakano Y, Murakami T, Fujisawa M. Efficacy of preoperative cine magnetic resonance imaging in evaluation of adhesion of renal cancer thrombus to inferior vena cava wall. J Vasc Surg Venous Lymphat Disord. 2022 Jul;10(4):908-915. doi: 10.1016/j.jvsv.2022.02.016. Epub 2022 Mar 18. — View Citation
Wagner B, Patard JJ, Mejean A, Bensalah K, Verhoest G, Zigeuner R, Ficarra V, Tostain J, Mulders P, Chautard D, Descotes JL, de la Taille A, Salomon L, Prayer-Galetti T, Cindolo L, Valeri A, Meyer N, Jacqmin D, Lang H. Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma. Eur Urol. 2009 Feb;55(2):452-9. doi: 10.1016/j.eururo.2008.07.053. Epub 2008 Aug 5. — View Citation
Wang B, Huang Q, Liu K, Fan Y, Peng C, Gu L, Shi T, Zhang P, Chen W, Du S, Niu S, Liu R, Zhao G, Li Q, Xiao C, Wang R, Li S, Wang M, Liu F, Wang H, Li H, Ma X, Zhang X. Robot-assisted Level III-IV Inferior Vena Cava Thrombectomy: Initial Series with Step-by-step Procedures and 1-yr Outcomes. Eur Urol. 2020 Jul;78(1):77-86. doi: 10.1016/j.eururo.2019.04.019. Epub 2019 May 16. — View Citation
Wang BS, Li YZ, Fang YY, Zhang SD, Ma LL. Imaging predictors for assessment of inferior vena cava wall invasion in patients with renal cell carcinoma and inferior vena cava tumor thrombus: a retrospective study. Chin Med J (Engl). 2020 Sep 5;133(17):2078-2083. doi: 10.1097/CM9.0000000000000828. — View Citation
* Note: There are 23 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall survival | The duration from the date of diagnosis to death or last follow-up, with no restriction on the cause of death. | From date of randomization until the date of lost follow-up or date of death from any cause, whichever came first, assessed up to 120 months | |
Secondary | Clinical manifestation | Clinical manifestation related to the renal carcinoma | From the clinical diagnosis until the surgery, an average of 3 weeks | |
Secondary | Mayo classification | A universal grading system for renal tumor thrombus. | The time once the preoperative imaging is assessed, up to 1 weeks. | |
Secondary | Primary tumor diameter | Diameter of the primary tumor. | The time once the preoperative imaging is assessed, up to 1 weeks. | |
Secondary | Preoperative tumor node metastasis (TNM) stage | TNM stage according to the preoperative imaging. | The time once the preoperative imaging is assessed, up to 1 weeks. | |
Secondary | IVC residual blood flow | Inferior vena cava residual blood flow according to ultrasonography. | The time once the preoperative imaging is assessed, up to 1 weeks. | |
Secondary | IVC vascular wall continuity | Inferior vena cava vascular wall continuity according to ultrasonography. | The time once the preoperative imaging is assessed, up to 1 weeks. | |
Secondary | IVC complete occlusion | Whether the inferior vena cava is completely occluded according to ultrasonography. | The time once the preoperative imaging is assessed, up to 1 weeks. | |
Secondary | IVC enhanced synchronization with tumor thrombus | Whether the inferior vena cava enhanced synchronization with tumor thrombus according to ultrasonography. | The time once the preoperative imaging is assessed, up to 1 weeks. | |
Secondary | Tumor thrombus move when breathe | Whether the tumor thrombus move when breathe according to ultrasonography. | The time once the preoperative imaging is assessed, up to 1 weeks. | |
Secondary | Maximum IVC anterior-posterior (AP) diameter | Maximum inferior vena cava anterior-posterior diameter according to CT/ MRI. | The time once the preoperative imaging was assessed, up to 1 weeks. | |
Secondary | Maximum coronal IVC diameter | Maximun coronal inferior vena cava diameter according to CT/ MRI. | The time once the preoperative imaging is assessed, up to 1 weeks. | |
Secondary | Maximum IVC AP diameter at the Rvo | Maximum inferior vena cava anterior-posterior diameter at the renal vein ostium according to CT/ MRI. | The time once the preoperative imaging is assessed, up to 1 weeks. | |
Secondary | Maximum coronal IVC diameter at the Rvo | Maximun coronal inferior vena cava diameter at the renal vein ostium according to CT/ MRI. | The time once the preoperative imaging is assessed, up to 1 weeks. | |
Secondary | Bland thrombus | The presence of bland thrombus in inferior vena cava according to CT/ MRI. | The time once the preoperative imaging is assessed, up to 1 weeks. | |
Secondary | growing against the direction of venous return (GADVR) | The presence of tumor thrombus growing against the direction of venous return according to CT/ MRI. | The time once the preoperative imaging is assessed, up to 1 weeks. | |
Secondary | Surgery approach | Radical nephrectomy and at least one kind of IVC thrombectomy (including IVC incision only, IVC partial resection, IVC diagonal resection, and IVC segmental resection) | The time once the surgery finished, an average of 10 days. | |
Secondary | Surgery time | Surgery time | The time once the surgery finished, an average of 10 days. | |
Secondary | Blood loss | Blood loss during surgery | The time once the surgery finished, an average of 10 days. | |
Secondary | Histological type | Histological type of the tumor according to pathological examination. | The time once the pathological specimen is assessed, up to 1 weeks. | |
Secondary | Postoperative TNM stage | TNM stage according to pathological examination. | The time once the pathological specimen is assessed, up to 1 weeks. | |
Secondary | Invaded vascular wall layer | The deepest Inferior vane cava vascular wall layer the tumor thrombus invaded. | The time once the pathological specimen is assessed, up to 1 weeks. | |
Secondary | Comorbidity occurence | The comorbidity occurence after surgery. | From the end of surgery until discharge, up to 3 weeks. | |
Secondary | Recurrence free survival | The duration from the date of diagnosis to death, last follow-up, or cancer recurrence. | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months | |
Secondary | Tumor metastasis | Location and time that the metastasis occurs. | Through study completion, an average of 3 year. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02248389 -
Evaluation of a Laparoscopic High Intensity Focused Ultrasound Probe for the Ablation of Small Renal Masses
|
Phase 1 | |
Completed |
NCT03900364 -
a Prospective Trial Comparing Robot-assisted Partial Nephrectomy Versus Laparoscopic Partial Nephrectomy
|
N/A | |
Completed |
NCT00158782 -
Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients
|
Phase 1 | |
Completed |
NCT03109015 -
Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing
|
Phase 2 | |
Completed |
NCT00363194 -
A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazopanib In Cancer Patients
|
Phase 1 | |
Completed |
NCT01012011 -
Regulatory Post Marketing Surveillance Study on Nexavar®
|
N/A | |
Completed |
NCT00842790 -
Impact of Predicting Anti-angiogenic Response in mRCC Using Functional Imaging
|
N/A | |
Completed |
NCT00529802 -
Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer
|
Phase 2 | |
Completed |
NCT00356460 -
Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma
|
Phase 1 | |
Completed |
NCT00387764 -
Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer
|
Phase 3 | |
Completed |
NCT00338884 -
Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer
|
Phase 2 | |
Completed |
NCT00095186 -
Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma
|
Phase 2 | |
Completed |
NCT00043368 -
PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)
|
Phase 2 | |
Completed |
NCT00079612 -
Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04489771 -
A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
|
Phase 2 | |
Completed |
NCT00516672 -
Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT05104905 -
A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma
|
Phase 1/Phase 2 | |
Terminated |
NCT03685591 -
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT03111901 -
Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05544929 -
A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers
|
Phase 1 |